Statement 7: In my clinical practice, I consider that the polymorphisms in the FSH and/or the beta variant of LH, could increase the risk of low response in patients with associated risk factors (advanced age, diabetes, obesity, chronic illness...). The gene discussed is BRD2; the disease is obesity disorder.